Quick answer
What is FOXO4-DRI?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk How this site works
FOXO4-DRI is a peptide, grouped on this site under Mitochondrial and longevity-associated peptides, and the 12 research records kept here are 7 from studies in rats or mice and 5 that do not state what kind of study it is.
The literature search returned 17 records. This site keeps 12 of them, which is 71 per cent of what came back.
What it is
This site puts it in the Mitochondrial and longevity-associated peptides group.
A senolytic peptide reported in the retrieved records to target the FOXO4 interaction with the p53 transactivation domain, releasing p53 in senescent cells.[1, 2]
Stated in the titles of the cited 2025 Nature Communications and 2025 Communications Biology papers.
What kind of records
The records kept here are animal and laboratory studies only.
That sentence is produced by counting, not by reading. What was counted: no interventional human trial record; 7 rodent and 0 in vitro records among 12.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 5 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature communications (2025). pmid:40593617
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications biology (2025). pmid:39994346